- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01230502
Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation
Donor Specific Regulation (DSR) Guided Tacrolimus Withdrawal to Myfortic Monotherapy in Liver Transplantation
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin- Madison
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects, ages 18 years and older who have received a primary liver transplant from a deceased donor for end stage liver disease *(ESLD).
- Women of child-bearing potential must have a negative serum pregnancy test at the time of screening and agree to use a medically acceptable method of contraception throughout the study and for 3 months following discontinuation of study treatment.
Exclusion Criteria:
- Recipients of multi-organ transplants.
- Recipients with positive crossmatch with their donor (current or previously).
- Subjects with a screening white blood cell count ≤ 2,000 mm3 or absolute neutrophil count (ANC) ≤ 1000, platelet count ≤ 100,000 mm3.
- Recipients with a hematocrit < 32.
- History of malignancy within 5 years of enrollment (except for adequately treated basal cell or squamous cell carcinoma of the skin).
- Subjects who are positive for hepatitis C, hepatitis B surface antigen, or HIV.
- Subjects with previous intolerance to full dose MPA agent.
- Subjects with a history of acute rejection within 6 months prior to study enrollment.
- Subjects who have had chronic ductopenic rejection.
- Subjects who had rejection in the first-year post-transplant and are less than 3 years post-transplant.
- Subjects who had rejection requiring treatment with thymoglobulin or Orthoclone-OKT3 (OKT3) at anytime post-transplant.
- Original cause of ESLD related to autoimmune diseases such as autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis.
- Subjects who have received an investigational drug within 4 weeks of study entry.
- Subjects with a history of a psychological illness or condition such as to interfere with the subject's ability to understand the requirements of the study.
- Female subjects who are pregnant or nursing or females who are unwilling to use contraception during the study.
- Subjects who are currently receiving any therapy for immunosuppression other than a MPA agent and tacrolimus.
- Subjects with a history of hepatocellular carcinoma (T2 >).
- Subjects with severe coexisting disease or presenting with any unstable medical condition which could affect study objectives.
- Subjects who have a known hypersensitivity to tacrolimus or mycophenolate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group 3: Donor Specific Regulation (DSR) -, standard of care
Subjects who test Donor Specific Regulation (DSR) negative will not be randomized to possible tacrolimus withdrawal, and will remain on standard of care immunosuppression.
|
Group 2 : Donor specific regulation (DSR) + standard of care: These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment. Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples Group 3 : Donor specific regulation (DSR) - standard of care: These subjects are those who were DSR negative and/or DSA positive at enrollment and therefore are not eligible for the withdrawal aspect of the study. These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment. These subjects will be asked to provide heath information and donate blood, exclusively for research testing, at the same 6 month intervals as those in the other two arms of the study, and will be followed for 24 months. |
Active Comparator: Group 2 Donor Specific Regulation (DSR) +; standard of care
Subjects that are Donor Specific Regulation (DSR) positive and randomized (1:1) to Group 2 will remain on standard of care immunosuppression.
|
Group 2 : Donor specific regulation (DSR) + standard of care: These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment. Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples Group 3 : Donor specific regulation (DSR) - standard of care: These subjects are those who were DSR negative and/or DSA positive at enrollment and therefore are not eligible for the withdrawal aspect of the study. These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment. These subjects will be asked to provide heath information and donate blood, exclusively for research testing, at the same 6 month intervals as those in the other two arms of the study, and will be followed for 24 months. |
Experimental: Group 1 Donor Specific Regulation (DSR) +, MPA monotherapy
Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy: Subjects that are Donor Specific Regulation (DSR) positive and randomized (1:1) to Group 1 will begin a taper off tacrolimus for 6 months, after repeat DSR testing at 6 months subject will either discontinue tacrolimus if they remain DSR negative or remain at reduced dose if converted to DSR positive |
Group 1 Donor Specific Regulation (DSR) +, MPA monotherapy Mycophenolate sodium : Myfortic therapy will be maintained at a target dose of 720mg BID. Tacrolimus doses will be lowered to achieve levels of 3-5 ng/ml. 6 months later, immunological monitoring will be repeated and tacrolimus will be completely discontinued if the subject remains DSR + without development of donor specific antibodies (DSA). Those who become DSR- or develop DSA will remain on a tacrolimus dose achieving levels of 3-5 ng/ml, and will not undergone any additional reduction. Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Modification of Diet in Renal Disease (MDRD) Estimation of Glomerular Filtration Rate (GFR)
Time Frame: 6 months post enrollment/randomization
|
This outcome measure is used to determine if the reduction of calcineurin inhibitor immunosuppression leads to improved native kidney function. Native kidney function is assessed using the Modification of Diet in Renal Disease (MDRD) estimation of glomerular filtration rate (GFR) from serum or plasma creatinine samples at the reported time points. Reference intervals include: Healthy 18 years and up: 60-120 mL/min/1.73 sqm Chronic kidney disease: GFR < 60 mL/min/1.73 sqm Kidney failure: GFR < 15 mL/min/1.73 sqm |
6 months post enrollment/randomization
|
Modification of Diet in Renal Disease (MDRD) Estimation of Glomerular Filtration Rate (GFR)
Time Frame: 12 months post enrollment/randomization
|
This outcome measure is used to determine if the reduction of calcineurin inhibitor immunosuppression leads to improved native kidney function. Native kidney function is assessed using the Modification of Diet in Renal Disease (MDRD) estimation of glomerular filtration rate (GFR) from serum or plasma creatinine samples at the reported time points. Reference intervals include: Healthy 18 years and up: 60-120 mL/min/1.73 sqm Chronic kidney disease: GFR < 60 mL/min/1.73 sqm Kidney failure: GFR < 15 mL/min/1.73 sqm |
12 months post enrollment/randomization
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Will Burlingham, PhD, University of Wisconsin, Madison
- Principal Investigator: Anthony D'Alessandro, MD, University of Wisconsin, Madison
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UW H-2010-0121
- CERL080AUS80T (Other Grant/Funding Number: Novartis Pharmaceuticals)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Transplant
-
Oslo University HospitalSouth-Eastern Norway Regional Health AuthorityNot yet recruitingLiver Metastases | Liver Transplant; Complications | Liver Cancer | Transplant | Transplant; Failure, Liver | Transplant; Complication, Rejection | Transplant Dysfunction
-
University Health Network, TorontoNot yet recruitingSolid Organ Transplant | Liver Transplant | Kidney Transplant | Heart Transplant
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)TerminatedLiver Transplant | Kidney TransplantUnited States
-
Astellas Pharma Europe Ltd.CompletedLiver Transplant | Kidney TransplantItaly, Spain, Belgium, Germany, Latvia, Canada, Korea, Republic of, Czechia, Austria, Finland, Belarus, Estonia, France, Hungary, Ireland, Netherlands, Poland, Portugal, Romania, Russian Federation, Slovakia, Sweden, Switzerland, United...
-
Memorial Bahçelievler HospitalCompletedLiver Diseases | Liver Failure | Liver Cirrhosis | Liver Transplant; Complications | Liver Transplant Rejection | Organ Transplant Failure or Rejection | Liver Transplant FailureTurkey
-
University of FloridaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedLiver Transplant | Kidney TransplantUnited States, Singapore
-
National Taiwan University HospitalUnknownRenal Transplant | Liver TransplantTaiwan
-
Paragonix TechnologiesEnrolling by invitationLiver Diseases | Liver Transplant Disorder | Liver Dysfunction | Liver Transplant RejectionUnited States
-
PilloxaTerminatedLiver Transplant; Complications | Kidney Transplant; ComplicationsSweden
-
National Institute of Allergy and Infectious Diseases...Rho Federal Systems Division, Inc.; Clinical Trials in Organ Transplantation...CompletedLiver Transplant Recipient | Living Donor (of the Respective Liver Transplant Recipient)United States
Clinical Trials on data and sample collection
-
Universitaire Ziekenhuizen KU LeuvenKU LeuvenRecruiting
-
Centre Hospitalier Intercommunal CreteilRecruitingEndometriosis | Pelvic NeoplasmsFrance
-
Istituto Scientifico Romagnolo per lo Studio e...Azienda Unità Sanitaria Locale della RomagnaRecruitingHaematological Malignancy | Haematologic DiseaseItaly
-
GlaxoSmithKlineCompletedRotavirus GastroenteritisGreece
-
H. Lee Moffitt Cancer Center and Research InstituteActive, not recruitingPancreatic Cancer | Cancer CachexiaUnited States
-
GlaxoSmithKlineCompletedInfections, RotavirusBulgaria, Latvia
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI); University of Miami; University of FloridaRecruitingPancreatic Cancer | Pancreatic CystUnited States
-
Danone Asia Pacific Holdings Pte, Ltd.National University Hospital, Singapore; University of Malaya; KK Women's and... and other collaboratorsRecruitingHealthySingapore, Malaysia, Thailand
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineFoundation of Tropical Medicine; Goncalo Moniz research center; Evandro Chagas...Terminated